Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Marine Gilabert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1868-3260; OpenAlex author ID A5058171637. Sources: ClinicalTrials.gov.

Their work

Papers
30 (first author 4, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
82
Papers, trials and grants by year

2012: 1 paper, 1 trial · 2013: none · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 6 papers · 2018: 3 papers · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 30

  1. Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review. First author DOI 10.3389/fonc.2023.1326676↗
  2. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  3. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  4. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  5. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  6. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  7. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
  8. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.12.001↗
  9. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
  10. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? Co-author DOI 10.1186/s12893-020-00835-3↗
  11. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement. Co-author DOI 10.1016/j.jviscsurg.2018.06.014↗
  12. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-019-1637-1↗
  13. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  14. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Co-author DOI 10.1016/j.suronc.2018.07.014↗
  15. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
  16. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  17. How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? Co-author DOI 10.1016/j.jgo.2017.08.007↗
  18. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1097/md.0000000000006544↗
  19. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000787↗
  20. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. Co-author DOI 10.1186/s12916-017-0936-z↗
  21. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  22. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Co-author DOI 10.1007/s12029-015-9774-4↗
  23. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  24. Prognostic value of PDL1 expression in pancreatic cancer. Co-author DOI 10.18632/oncotarget.11685↗
  25. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. First author DOI 10.18632/oncotarget.9861↗
  26. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. First author DOI 10.1016/j.ajpath.2014.11.029↗
  27. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  28. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗
  29. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. Co-author DOI 10.1002/jcp.24580↗
  30. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … First author DOI 10.1093/annonc/mds135↗

Trials 1

  1. Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors Principal investigator NCT01692873↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olivıer Turrini · 22 shared papers, 2012–2023 · strength 1.65
  2. Jean‐Robert Delpéro · 15 shared papers, 2012–2021 · strength 1.18
  3. Marc F. Giovannini · 15 shared papers, 2012–2021 · strength 0.99
  4. Jonathan Garnier · 9 shared papers, 2016–2023 · strength 0.90
  5. Jean‐Luc Raoul · 13 shared papers, 2012–2018 · strength 0.78
  6. Ugo Marchèse · 7 shared papers, 2019–2021 · strength 0.76
  7. Juan Iovanna · 11 shared papers, 2014–2021 · strength 0.58
  8. Pauline Duconseil · 9 shared papers, 2015–2021 · strength 0.52
  9. Laurence Moureau-Zabotto · 6 shared papers, 2012–2020 · strength 0.49
  10. Odile Gayet · 9 shared papers, 2015–2021 · strength 0.47
  11. Nelson Dusetti · 9 shared papers, 2015–2021 · strength 0.47
  12. Julien Taı̈eb · 3 shared papers, 2018–2022 · strength 0.32
  13. Rémy Nicolle · 5 shared papers, 2017–2021 · strength 0.32
  14. Véronique Secq · 6 shared papers, 2015–2018 · strength 0.26
  15. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  16. Édouard Auclin · 2 shared papers, 2022 · strength 0.26
  17. Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
  18. Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
  19. Dominique Béchade · 2 shared papers, 2022 · strength 0.26
  20. Julien Edeline · 2 shared papers, 2022 · strength 0.26
  21. Simon Pernot · 2 shared papers, 2022 · strength 0.26
  22. David Tougeron · 2 shared papers, 2022 · strength 0.26
  23. Brice Chanez · 2 shared papers, 2017–2023 · strength 0.25
  24. Céline Loncle · 6 shared papers, 2015–2017 · strength 0.25
  25. Mehdi Ouaïssi · 6 shared papers, 2015–2017 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.